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T

o improve the efﬁcacy of safe vaccines against global pathogens like HIV-1, “heterologous prime-boost” strategies are
being tested, in particular priming with a DNA vaccine and
boosting with a recombinant viral vector (1, 2). During heterologous prime-boosting, vaccine antigens are introduced in different
vectors to reduce the risk of anti-vector immunity; e.g., adenoviral
vectors quickly induce neutralizing antibodies minimizing the
response to multiple doses. Here, we have pursued a “complementary” prime boost vaccination strategy, in which the two vaccines induce different types of immunity and no microbial vectors
are required.
We previously reported that a protein-based vaccine becomes
more immunogenic for mice when it is directly targeted to
dendritic cells (DCs), the principal antigen-presenting cells for
initiating T cell immunity (3), along with a suitable adjuvant to
stimulate DC maturation. Selective and efﬁcient antigen targeting to DCs was achieved by introducing HIV gag (4, 5) into a
monoclonal antibody (mAb) to a DC-restricted, antigen uptake
receptor, DEC-205 or CD205. Synthetic double-stranded RNA,
polyIC, proved to be an effective adjuvant for this protein vaccine (5). Nevertheless, the achieved immunity was primarily
comprised of Th1-type CD4+ T cells whereas, in contrast, DNAand adenoviral vector-based vaccines induced higher CD8+ T
cell frequencies (4).
It is known that CD4+ T cells provide essential help for generating CD8+ T cell responses (6–11). Here, we will show that
protective CD8+ T cell immunity to a DNA vaccine is improved by
priming a helper T cell response with a DC-targeted protein vaccine. One component of the improved protection is a more rapid
accumulation of gag-speciﬁc CD8+ T cells to a mucosal infection
challenge site.
www.pnas.org/cgi/doi/10.1073/pnas.1000621107

Results
DC-Targeted Protein Enhances Protection Afforded by a DNA Vaccine.

To test the protection afforded by protein and DNA vaccines, we
ﬁrst compared two doses of DC-targeted, DEC-gag protein vaccine to two doses of gag plasmid DNA vaccine, given 1 month
apart, and we used a higher intranasal (i.n.) dose of challenge virus
than our prior studies (4, 5). Both protein and DNA forms of
vaccination induced protection against weight loss (Fig. S1A) and
an ∼100-fold reduction to challenge recombinant vaccinia virus
(Fig. 1A; compare orange and green with black).
Next, to try to improve protective immunity, we primed mice with
a single dose of DEC-targeted gag protein vaccine followed by a
boost with gag plasmid DNA 4–8 weeks later. Twelve weeks after
boosting, mice were challenged with recombinant vaccinia gag,
whereupon weight loss was monitored daily and lung virus titers
determined as described (4, 5, 12). Again, mice receiving two doses of
DNA exhibited some protection against weight loss (Fig. S1B,
orange) and also an ∼100-fold reduction in virus titers (Fig. 1B,
orange). A single dose of DNA vaccine did not protect against weight
loss and reduced virus titers only by 10-fold (Fig. 1B, red). However,
priming with DEC-gag plus polyIC protein vaccine followed by
plasmid DNA vaccine provided superior protection against weight
loss to two DNA vaccines (Fig. 1B, *) and reduced virus titers in the
lung by an average of 5,000-fold in three experiments (Fig. 1B, dark
blue), which titers were signiﬁcantly lower than mice vaccinated twice
with DNA (P < 0.005). The control for this and the following
experiments was a control Ig (not binding to DCs) gag protein vaccine followed by a single DNA boost, but this control prime boost
strategy offered only 1 log of protection (Fig. 1B, turquoise). We will
use the term “complementary” prime boost to describe DEC-gag
protein prime plus DNA boost, because we will show that each part
of the vaccine induces a distinct type of immune response.
T Cells Provide Protection After a Complementary Protein Prime-DNA
Boost Vaccine. To assess the contribution of T cells to protective

immunity, we treated mice with either rat IgG control mAb or with
depleting mAbs to CD4 and CD8 before the i.n. challenge with
recombinant vaccinia gag virus. We veriﬁed these mAbs selectively
depleted CD4+ and CD8+ CD3+ T cells. In addition, we found
that treatment of mice with control mAb did not interfere with the
observed 3 logs of protection afforded by the complementary
prime boost vaccine to vaccinia gag challenge (Fig. 2A Upper Left,
dark blue bar). However, depletion of either CD4+ or CD8+ T
cells reduced protection signiﬁcantly (10- to 30-fold) for the mice
vaccinated with the DEC-gag prime DNA boost regimen but did
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To improve the efﬁcacy of T cell–based vaccination, we pursued the
principle that CD4+ T cells provide help for functional CD8+ T cell
immunity. To do so, we administered HIV gag to mice successively
as protein and DNA vaccines. To achieve strong CD4+ T cell immunity, the protein vaccine was targeted selectively to DEC-205, a receptor for antigen presentation on dendritic cells. This targeting helped
CD8+ T cell immunity develop to a subsequent DNA vaccine and
improved protection to intranasal challenge with recombinant vaccinia gag virus, including more rapid accumulation of CD8+ T cells in
the lung. The helper effect of dendritic cell-targeted protein vaccine
was mimicked by immunization with speciﬁc MHC II binding HIV gag
peptides but not peptides from a disparate Yersinia pestis microbe.
CD4+ helper cells upon adoptive transfer allowed wild-type, but not
CD40−/−, recipient mice to respond better to the DNA vaccine. The
transfer also enabled recipients to more rapidly accumulate gagspeciﬁc CD8+ T cells in the lung following challenge with vaccinia
gag virus. Thus, complementary prime boost vaccination, in which
prime and boost favor distinct types of T cell immunity, improves
plasmid DNA immunization, including mobilization of CD8+ T cells to
sites of infection.

A

Protein Priming Improves CD8+ T Cell Immunity to a DNA Vaccine. To
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Fig. 1. DC-targeted protein vaccine enhances protection from DNA vaccine.
(A) Groups of ﬁve female 6- to 10-week-old CxB6 F1 mice were primed and
boosted with protein (5 μg of anti-DEC HIV gag p41 plus 50 μg of polyIC) or
DNA vaccine (10 μg of HIV gag p41 DNA) i.m. 8 weeks apart. Twelve weeks
after the boost, a lethal dose (105 PFU) of recombinant vaccinia gag was
given i.n., and vaccinia virus titers in the lung (PFU/lung) were measured 7
days later. (B) As in (A), but complementary protein-prime DNA-boost vaccination (blue) was evaluated to induce protection as monitored by lung
vaccinia virus titers (mean ± SD of three experiments).

not completely eliminate protection (Fig. 2A, two right bars). We
then treated vaccinated mice with either control Ig or a combination of mAbs to CD4 and CD8 (Fig. 2B, Left and Right).
Depletion of both CD4+ and CD8+ T cells before challenge
eliminated protection from weight loss (Fig. S1 C and D) and
increased lung virus titers (Fig. 2B, compare dark blue bars in Left
and Right). Therefore, the superior protection from complementary prime boost requires both CD4+ and CD8+ T cells.

A

assess T cell immunity after vaccination with DEC-targeted gag
protein prime followed by gag DNA boost, we measured CD4+
and CD8+, gag-speciﬁc T cells at the single-cell level. One dose of
DNA elicited weak CD4+ and CD8+ immunity (Fig. 3 A–C, red
second row of data) whereas two doses induced a stronger
response (orange, third row of data). Prior data had shown that
one dose of DEC-targeted gag protein vaccine, together with
polyIC, induced weak CD4+ T cell immunity, whereas two doses
led to strong but primarily CD4+ T cell immunity (5) (and see
below). In three experiments, priming with one dose of a DC
targeted protein vaccine, but not nontargeted control Ig-gag vaccine, resulted in strong combined CD4+ and CD8+ T cell
immunity to a single dose of DNA vaccine (Fig. 3 A–C, compare
fourth and ﬁfth rows, turquoise and dark blue). IFN-γ production
by CD4+ T cells following complementary prime boost also was
signiﬁcantly higher than with two doses of DNA [Fig. 3, ** (P <
0.01)]. For mice primed with either two doses of DNA or complementary prime boost, the gag-speciﬁc CD8+ T cells were also
capable of proliferating to HIV gag (Fig. 3D, *). However, CD4+ T
cells immunized with the complementary prime boost approach
expanded signiﬁcantly better than CD4+ T cells immunized with
two doses of DNA [Fig. 3D, *, open bars (P < 0.05)]. The gagspeciﬁc CD4+ and CD8+ T cells persisted at least 4 months after
boosting in two long-term experiments (Fig. 3E, dark blue). Thus,
complementary prime boosting provides improved and long-lived
CD4+ and CD8+ T cell immunity to one dose of DNA vaccine.
Complementary Protein Prime-DNA Boost Allows for More Rapid
Accumulation of CD8+ T Cells to an Infection Challenge Site. Because

the above studies did not reveal a major quantitative difference in
CD8+ T cells induced by two doses of DNA (“homologous” prime
boost) vs. complementary prime boost, we asked whether the
priming with DEC gag vaccine improved the quality of the CD8+ T
cell response by examining the rapidity with which gag-speciﬁc
CD8+ T cells were mobilized to a site of infection. In three
experiments, 120 days after vaccination, we challenged the mice
with recombinant vaccinia gag i.n. and then examined the site of
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Fig. 2. CD4+ and CD8+ T cells protect mice after protein-prime DNA-boost vaccine. (A) Mice vaccinated as indicated on the x axis and Fig. 1 were treated with
control rat Ig or depleting antibodies to CD4 or CD8 at days −3, −2, and −1 before airway challenge with recombinant vaccinia gag virus (mean of two
experiments). (B) As in (A), mice were treated with control rat IgG (Left) or depleted of both CD4+ and CD8+ T cells (Right) before challenge with vaccinia gag
and measurement of vaccinia virus titers (PFU/lung).

4282 | www.pnas.org/cgi/doi/10.1073/pnas.1000621107

Nchinda et al.

A

C

B
Mean % total IFN-γ forming
CD4 + T cells
0

0.2

0.4

0.6

0.8

1.0

0

1

2

3

D

Tetramer positive
CD8 + T cells

Mean% total IFN-γ forming
CD8 + T cells

0

4

2

4

T cell proliferation and
IFN-γ formation

6

8

10

12

1

3

5

7

no
vaccine

9

11

13

15

CD4 T cells, open
CD8 T cells, filled

DNA
boost only
DNA
prime boost
Control-p41
prime,
DNA boost
DEC-p41
prime,
DNA boost

**

E

IFN-γ forming
CD8 + T cells

Tetramer positive
CD8 + T cells
8

Mean
%

*

0.8

3.1

6

2.1

0
7

30

120

DNA
boost only

0.6

DNA
prime boost

0.4

4
2

IFN-γ forming
CD4 + T cells

1.1

0.2

0.1

0
7

30

DEC-p41 prime
DNA boost
30

7

120

120

Days post DNA vaccine boost

Fig. 3. Complementary protein prime DNA boost vaccination induces combined and durable CD4+ and CD8+ T cell immunity. (A) Female CxB6 F1 mice were
vaccinated as in Fig. 1. Thirty days after the DNA boost, bulk splenocytes were assessed for T cell immunity. (A and B) Splenocytes were restimulated either
with unreactive peptides or with an HIV gag peptide mix, and IFN-γ production in response to peptide was evaluated by intracellular cytokine staining 6 h
later in CD4+ (A) or CD8+ (B) CD3+ T cells. (C) HIV gag-speciﬁc CD8+ T cells were enumerated by binding of gag tetramers. (D) HIV gag-dependent T cell
proliferation and IFN-γ production was measured in CFSE-labeled splenocytes restimulated for 4 days with gag-speciﬁc peptides (or nonspeciﬁc control
peptides), followed by intracellular staining for IFN-γ in CFSE-low CD4+ and CD8+ T cells. All data are mean ± SD of three experiments, each involving ﬁve F1
mice per group. (E) Means of two experiments to follow the longevity of the immune response in vaccinated mice for 120 days.
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B

100

7days post challenge
Vaccinia-HIV gag

DNA
boost only

Spleen d4
Spleen d7
Lung d4
Lung d7

Downloaded at Rockefeller University Library on August 18, 2020

DEC-p41
prime
DNA boost

0.8

Spleen

Lungs

0.4

0.24

0.2

0.1

Lungs

0.1

0.5

2

58

41 62

37

58

42 61

38

0.2

0.1 0.4

39

0.1

2

6

39 63

0.2

DNA
prime boost

DNA
prime boost
Control-p41
prime
DNA boost

no
vaccine

Gag tetramer

Spleen

no
vaccine

7days post challenge
Vaccinia-OVA

61

*

DEC-p41
prime
DNA boost

0.2

0.2

72

28

27

61

2

90

0.1

49

24

78

38 54

44

0.2

5

0.3

22 62

36
CD8

Fig. 4. Complementary protein prime DNA boost vaccine allows for more rapid accumulation of CD8+ T cells to an infection challenge site. As in Fig. 3, mice
were vaccinated (y axis) and 90 days after the boost challenged with a lethal dose of vaccinia gag i.n. At day 4 and day 7, lungs were dissociated to enumerate
HIV gag-speciﬁc tetramer binding cells. (A) A rapid accumulation of speciﬁc CD8+ T cells in the lungs after DC-targeted protein prime-DNA boost vaccine.
Illustrative FACS data are in Fig. S3. Arrows point to rapidly accumulating gag-speciﬁc CD8+ T cells early (day 4) in mice challenged after two doses of DNA
vaccine or complementary prime-boost vaccine. Shown are means of two experiments. (B) In HIV gag-vaccinated mice, gag-speciﬁc CD8+ T cells accumulate
when mice are challenged with vaccinia gag (Left) but not vaccinia-OVA (Right).
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challenge infection, the lungs, as well as the spleen 4 and 7 days
later. Priming with DEC-gag p41 plus polyIC followed by boosting
with one dose of DNA led to a better accumulation of CD8+ T cells
to the lung (P = 0.05) than a single dose or two doses of DNA
vaccine (Fig. 4A, compare lung day 4 data at arrows). To establish
that the accumulation of gag-reactive CD8+ T cells in the lungs
was speciﬁc to vaccine antigen, we showed that gag-reactive cells
accumulated when mice were challenged with vaccinia gag but not
vaccinia OVA (Fig. 4B). Therefore, complementary prime boost
vaccination leads to more rapid accumulation of CD8+ T cells
upon vaccinia gag challenge, and this is gag antigen-dependent not
vaccinia "inﬂammation"- or infection-dependent.

IFN-γ in response to HIV gag antigen (Fig. S3; compare Left and
Right). Complementary prime boost did not allow for reduced
virus titers in lungs (Fig. 6A; compare fourth and ﬁfth rows). When
we also followed CD8+ T cell accumulation to a challenge site, the
CD40−/− mice lacked gag-speciﬁc CD8+ T cells in the lungs, with
either two DNA vaccines or the complementary prime boost
strategy (Fig. 6B; compare thick and thin arrows for wild-type and
CD40−/− mice). Thus, our prime boost vaccination increased lung
CD8+ T cells in a CD40-dependent manner.
To determine whether CD40 was operating at the level of
antigen-presenting cells, we adoptively transferred gag-primed
CD4+ T cells into wild-type or CD40−/− mice and then boosted
with DNA vaccine. Before T cell transfer, we ﬁrst conﬁrmed priming of gag-speciﬁc CD4+ T cells in the donor mice (Fig. S4). One
day later the mice were boosted with a single dose of gag DNA, and
4 weeks later the mice were challenged i.n. with vaccinia gag. Upon
challenge, wild-type, but not CD40−/−, mice showed a 10 log-fold
reduction in lung virus titer when provided with immune CD4+ T
cells [Fig. 6C; compare two left blue bars (P < 0.018)]. Thus,
adoptively transferred wild-type CD4+ T cells do not enhance the
protection afforded by a DNA vaccine in CD40−/− mice.

pestis as described (13). As expected, the peptides primed the mice
in a speciﬁc way; i.e., CD4-negative T cells were primed to CD8restricted gag peptides (Fig. S2, arrow second row) whereas CD4+
T cells were primed selectively to either LcrV or gag CD4restricted peptides (Fig. S2, arrows, third and fourth rows).
In three experiments, we again observed strong CD8+ responses
to a DNA boost in mice primed with DEC-gag p41 protein vaccine
plus polyIC but not control Ig gag p41 plus polyIC (Fig. 5A;
compare turquoise and dark blue). Importantly, when we replaced
the protein vaccine with peptides, only helper peptides recognized
by CD4+ T cells, and not the peptide recognized by gag-speciﬁc
CD8+ T cells, were able to prime for a strong CD8+ T cell response
to DNA gag vaccine (Fig. 5A, lower two rows). Thus, priming
CD4+ T cells with peptides allows for better CD8+ T cell
responses to a single dose of DNA vaccine. Next, to evaluate the
speciﬁcity of the help provided by CD4+ T cells, we immunized
CxB6 F1 mice with either HIV gag- or LCRV CD4-restricted
peptides and boosted with HIV gag DNA as above. Only gag CD4restricted peptides enhanced CD8+ T cell responses to gag DNA
vaccine (P < 0.03) (Fig. 5B; compare ﬁfth and sixth rows, ** and *).
This indicated that help provided to CD8+ T cells was cognate
antigen-dependent.

Discussion
Protein and DNA vaccines, though safe, do not induce a high
frequency of CD4+ and CD8+ T cells as detected by cytokine
production and cell proliferation. Our results show that antigenspeciﬁc CD4+ helper T cells can be elicited by a priming dose of a
DEC-targeted protein vaccine, and this improves the induction of
T cell immunity with a DNA vaccine. In addition to strong, combined, durable T cell immunity, this approach improved protection
against a challenge with recombinant vaccinia gag virus in the

Complementary Protein Prime-DNA Boost Vaccine Requires CD40. To

begin to understand mechanisms required for the helper effect of a
DC-targeted protein vaccine, we pursued the fact that helper T
cells express CD40L, which acts to mature DCs presenting antigens to CD8+ T cells (10, 14–16). Indeed, CD40−/− mice developed reduced CD4+ and CD8+ T cell immunity to vaccination
with either two doses of DNA or complementary protein prime
DNA boost, including T cells that could proliferate and produce
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Fig. 5. Helper HIV gag peptides improve CD8 T cell responses to DNA vaccine. Two experiments in which CxB6 F1 mice were vaccinated as in Figs. 2 and 3, but
we added groups of mice primed with HIV gag peptides recognized by CD4+ and CD8+ T cells, or LcrV CD4-restricted peptides, to compare with DEC gag p41
protein vaccine (y axis). Thirty days after the DNA vaccine boost we measured HIV gag-speciﬁc IFN-γ-producing CD4+ and CD8+ IFN-γ-secreting T cells, and
tetramer binding CD8+ T cells. Shown are means of two experiments.
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airway. We are also ﬁnding that the DNA vaccine can either precede or follow the DEC-gag protein vaccine.
Multiple strategies have been exploited to augment the
induction of effective immunity following DNA vaccination
(reviewed in refs. 17–19), including the coadministration of tolllike receptor ligands (20). Importantly, in prime boosted mice
challenged with vaccinia gag, the CD8+ gag-speciﬁc T cells
induced by our complementary prime boost approach were more
rapidly mobilized in the lung. A similar ﬁnding has been reported
in an elegant report carried out during our study; i.e., that helper
cells formed during infection improved the inﬂux of CD8+ T cells
to the infection site (21).
CD4+ helper cells are known to improve CD8+ T cell immunity
(reviewed in ref. 22). CD4+ T cells can provide IL-2 required to
sustain CD8+ T cell memory, although these CD4+ T cells do not
have to be primed to a speciﬁc antigen (23). Alternatively, Heath
et al. (24), in studies of the strong CD8+ T cell response to inﬂuenza and HSV, showed that CD4+ and CD8+ T cells each had to
respond to the same antigenic component of the virus. We also
found, consistent with previous data (24, 25), that the CD4+ and
CD8+ T cells needed to recognize peptides from the same protein.
With respect to mechanism, CD40 was required for the protective efﬁcacy of the complementary prime boost vaccination.
CD40L is expressed by CD4+ helper T cells, and one consequence
of CD40L function is to ligate CD40 on DCs, driving their maturation and enhancing immunity to antigens presented by DCs (10,
14–16). In addition, intravital microscopy of intact lymph nodes
indicates that CD4+ helper cells recruit CD8+ T cells to the
antigen presenting DCs (26) by producing CCL3 and CCL4 chemokines (27), the same chemokines that block HIV infection via
CCR5 coreceptors (28). We veriﬁed that the helper effect from
Nchinda et al.

priming CD4+ T cells operated through CD40 on non-T cells,
presumably DCs. In addition, we found that CD40-mediated help
led to the more rapid accumulation of CD8+ T cells at a site of
challenge infection, the lung.
There is concern that HIV-speciﬁc CD4+ T cells could provide a
permissive environment for HIV replication (29), but the reciprocal is also possible, that CD4+ helper cells produce chemokines
that block the CCR5 coreceptor (30) and, as we emphasize here,
valuably help protective CD8+ T cell (and antibody) responses
(31). In particular, antigen-speciﬁc CD4+ T cells allow for the
more rapid accumulation of antigen-speciﬁc CD8+ T cells after
challenge with a pathogenic virus. In macaques showing protection
after vaccination with attenuated delta nef SIV vaccine (32) or
recombinant adenovirus-SIV gag (33), broad gag-speciﬁc CD4+ T
cell immunity was evident, raising the possibility that gag-speciﬁc
CD4+ T cells can be helpful, not harmful, in resisting immunodeﬁciency virus. A key distinction is that the CD4+ T cells should
be virus-speciﬁc to provide help for strong protective CD8+
resistance as opposed to more abundant activated T cells speciﬁc
for disparate antigens, which can serve as a permissive site for SIV
and HIV but fail to offer protective value.
The complementary prime boost approach, in which DC-targeted
protein vaccine favors helper cell formation and DNA vaccine
favors killer cell formation, does not require microbial vectors, thus
simplifying vaccine manufacture; it also reduces antivector
immunity as well as competition between peptides presented from
vector and vaccine antigens. By directing the helper response to
deﬁned proteins, it may be feasible to improve the quality of the
CD8+ T cell response to DNA and other vaccines, and potentially
resistance to infectious and malignant diseases.
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Fig. 6. Help from DC-targeted protein vaccine requires CD40. (A) Female wild-type and CD40−/− CxB6 F1 mice were vaccinated as indicated on the y axis.
Thirty days after the last DNA boost mice were challenged with vaccinia gag i.n. to assess protection in terms of body weight and lung virus titers as in Fig. 1.
(B) Likewise, during the challenge with vaccinia gag the numbers of CD8+ gag-speciﬁc tetramer binding cells were measured at day 4 and day 7 in spleen and
lungs. (C) Female CxB6 F1 mice were vaccinated with DEC-p41 and polyIC twice. A spleen equivalent of CD4+ T cells was then adoptively transferred into wildtype or CD40−/− CxB6 F1 mice and boosted with a single dose of HIV gag DNA. Four weeks later the mice were challenged with vaccinia gag. Data represent a
mean ± SD of 10 mice per group.

Materials and Methods
Mice and DNA Vaccination. CxB6 F1 mice from Harlan were maintained under
speciﬁc-pathogen-free conditions and used at 6–10 weeks, according to
Rockefeller University guidelines. DNA vaccine (prepared with Qiagen endotoxin free GIGA kit) was injected i.m. in saline with electroporation (Ichor
Medical Systems) and 1.25 mg per mouse nembutal anesthesia i.p. The skin
above the anterior tibialis muscles was shaved and sterilized with ethanol.
Antibodies. Antibodies to CD3, CD4, CD8α, and cytokines (IFN-γ, IL-2, and TNF-α)
were purchased from BD Biosciences-Pharmingen.
Fusion HIV gag mAbs. These were generated as described (4, 5). Western
blotting with HRP-anti-p24 (ImmunoDiagnostics) was used to determine the
speciﬁcity of the gag fusion constructs. mAb binding was veriﬁed on CHO cells
stably transfected with mouse DEC-205 by FACS, using either PE-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch) or FITC-conjugated anti-p24
(Coulter KC57-FITC). All mAbs were endotoxin-free in limulus amebocyte
lysate assay (QCL-1000; Cambrex).
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Immunizations. Female CXB6 F1 mice were injected once i.p. with fusion mAb
together with polyIC (50 μg; Invivogen) as adjuvant. Eight weeks later, mice
were boosted with 10 μg of HIV gag p41 DNA. One hundred micrograms of
peptides was injected i.m. with or without polyIC. Four weeks after the last
peptide injection, mice were boosted with 10 μg of HIV gag p41 DNA.

University). The 90-member gag p41 library was resuspended at 1 mg/mL each
peptide in 100% DMSO. For FACS, dead cells were excluded using LIVE/DEAD
ﬁxable dead stain kit (Aqua LIVE/DEAD; Invitrogen). After blocking Fcγ
receptors, the cells were stained with antibodies to CD3-paciﬁc blue, CD4percp, CD8-alexa-750, and Aqua LIVE/DEAD stain for 20 min at 37 °C. Cells were
washed, ﬁxed (Cytoﬁx/Cytoperm; BD Biosciences), permeabilized with Permwash and stained with antibodies to IFN-γ (IFN-γ-alexa-700), IL-2 (IL-2-FITC),
and TNF-α (TNF-α-PE-CY7) for 15 min at room temperature. All antibodies were
from eBioscience, and HIV gag CD8 tetramers (AMQMLKETI) were H-2Kd PE
from Beckman Coulter. We use BD Biosciences LSRII with data analysis in
FlowJo (Tree Star).
Vaccinia gag Protection Assays. Nembutal-anesthetized mice were challenged
i.n. with 105 PFU per mouse recombinant vaccinia gag virus in 35 μL of PBS with
Mg/Ca. A negative control was vaccinia-OVA virus. Animal weights (groups of
ﬁve) were determined daily for 7 days following challenge. Then, mice were
euthanized, and their lungs were harvested, homogenized in transport
medium (0.1% gelatin in PBS), and stored in duplicate at –80 °C before virus
titration. Lung virus titers of individual mice in each group were determined by
plaque assay on monolayers of CV-1 cells as described (4, 5, 12).
Statistics. Postchallenge mean vaccinia lung virus titers and mean percentage
in weight loss were compared between vaccination groups using one-tailed
Student’s t test. Differences were considered signiﬁcant at P < 0.05 after
analysis using Prism 3 (GraphPad).

Assays for HIV-Speciﬁc Immune T Cells. To detect HIV gag–speciﬁc T cell
responses, bulk splenocytes were restimulated with peptides spanning the
entire gag p41 sequence (4, 5, 12) or a negative unreactive control peptide mix
consisting of HIV gag p17 pool 1 in the presence of 2 μg/mL anti-CD28 (clone
37.51) for 6 h, adding 10 μg/mL brefeldin A (Sigma-Aldrich) for the last 4 h to
accumulate intracellular cytokines. Overlapping (staggered by 4 aa) 15-mer
peptides spanning LcrV (13) and HIV gag p41—i.e., HIV gag p17 and HIV gag
p24 (4)—were synthesized by the Proteomic Resource Center (The Rockefeller
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